PERNIX THERAPEUTICS HOLDINGS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Net revenues
Costs and operating expenses:
Cost of product sales
Selling, general and administrative expense
Research and development expense
Loss from operations of the joint venture
Depreciation and amortization expense
Change in fair value of contingent consideration
Loss from impairments of intangibles, goodwill and other assets
Loss on sale of PML (including impairment charge)
Gain from legal settlement
Restructuring costs
Total costs and operating expenses
Loss from operations

Other income (expense):
Interest income
Change in fair value of put right
Change in fair value of contingent consideration
Gain on contingent consideration and put right
Interest expense, net
Gain on sale of investment
Interest expense
Gain on sale of assets
Change in fair value of derivative liability
Gain from exchange of debt
Foreign currency transaction gain (loss)
Cost of inducement
Loss on extinguishment of debt
Total other expense, net
Loss before income tax expense
Income tax expense
Net loss

Other comprehensive loss
Unrealized Gain (loss) during period, net of tax of $0 and $0, respectively
Reclassification adjustment for net gains included in net loss, net of tax of $0, $0 and ($1,332), respectively
Comprehensive loss
Net loss per share, basic
Net loss per share, diluted
Weighted-average common shares, basic
Weighted-average common shares, diluted

Comments